Pharmacoeconomics of darunavir

References

• Schackman BR, Gebo KA, Walensky RP et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care44(11), 990–997 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA304(3), 321–333 (2010).
   PubMed Web of Science ®Google Scholar
• Wilson LE, Gallant JE. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin. Infect. Dis.48(2), 214–221 (2009).
   PubMed Web of Science ®Google Scholar
• Chen RY, Accortt NA, Westfall AO et al. Distribution of healthcare expenditures for HIV-infected patients. Clin. Infect. Dis.42(7), 1003–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Gebo KA, Fleishman JA, Conviser R et al. Contemporary costs of HIV healthcare in the HAART era. AIDS24(17), 2705–2715 (2010).
   PubMed Web of Science ®Google Scholar
• McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs69(4), 477–503 (2009).
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Joyce G, McCaffrey DF et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N. Engl. J. Med.344(11), 817–823 (2001).
   PubMed Web of Science ®Google Scholar
• Freedberg KA, Losina E, Weinstein MC et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med.344(11), 824–831 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson M, Hill A, Smith C. Analysis of increased efficacy versus additional cost of antiretrovirals for therapy-experienced patients with HIV infection. Presented at: 10th European AIDS Conference (EACS). Dublin, Ireland, 17–20 November 2005 (Poster PE19.5/5).
   Google Scholar
• Martin S, Foley K, Baser O. Incremental medical costs associated with increased changes in HAART regimens in a US patient sample. Presented at: 4th International AIDS Society (IAS) Conference. Sydney, Australia, 22–25 July 2007 (Poster WEPEB047).
   Google Scholar
• Caekelbergh K, Moeremans K, Annemans L et al. Cost of care for HIV/AIDS in Belgium according to disease stage. Presented at: 11th European AIDS Conference (EACS). Madrid, Spain, 24–27 October 2007 (Poster P19.5/01).
   Google Scholar
• Hill A, Gebo K. Predicting HIV care costs using CD4 counts from clinical trials. Am. J. Manag. Care.13(9), 524–528 (2007).
   PubMed Web of Science ®Google Scholar
• Schackman BR, Freedberg KA, Weinstein MC et al. Cost–effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch. Intern. Med.162(21), 2478–2486 (2002).
   PubMed Web of Science ®Google Scholar
• Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat. Med.9(7), 867–873 (2003).
   PubMed Web of Science ®Google Scholar
• Pozniak A, Jayaweera D, Hoy J, De Meyer S, De Paepe E, Spinosa-Guzman S. Efficacy of darunavir/ritonavir in treatment-experienced HIV-1 infected patients at 96 weeks in the POWER 1 and 2 trials. Presented at: 11th European AIDS Conference (EACS). Madrid, Spain, 24–27 October 2007.
   Google Scholar
• Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet369(9568), 1169–1178 (2007).
   PubMed Web of Science ®Google Scholar
• Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS21(6), F11–F18 (2007).
   PubMed Web of Science ®Google Scholar
• Katlama C, Esposito R, Gatell JM et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS21(4), 395–402 (2007).
   PubMed Web of Science ®Google Scholar
• Dubois D, Smets E, Vangeneugden T et al. Improved quality of life in treatment-experienced HIV patients treated with TMC114/r versus control protease inhibitors: results of POWER 1 and 2 functional assessment of HIV infection (FAHI). Presented at: 16th International Aids Conference (IAC). Toronto, Canada, 13–18 August 2006 (Poster TUPE0069).
   Google Scholar
• Pozniak A, Arastéh K, Molina JM et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients. Presented at: 9th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 9–13 November 2008 (Poster P24).
   Google Scholar
• Katlama C, Bellos N, Grinsztejn B et al. POWER 1 and 2: Combined final 144-week efficacy and safety results for darunavir/ritonaivr (DRV/R) 600/100 mg BID in treatment-experienced HIV patients. Presented at: 9th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 9–13 November 2008 (Poster P21).
   Google Scholar
• Banhegyi D, Katlama C, Da Cunha C, et al. Phase III TITAN Week 96 final analysis: Efficacy/safety of darunavir/r (DRV/r) vs lopinavir/r (LPV/r) in LPV/r-naive, treatment-experienced, patients. Presented at: 9th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 9–13 November 2008.
   Google Scholar
• Madruga JV, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled Phase III trial. Lancet370(9581), 49–58 (2007).
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS23(17), 2289–2300 (2009).
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir. Ther.15(7), 1045–1052 (2010).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med.359(4), 355–365 (2008).
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med.359(4), 339–354 (2008).
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin. Infect. Dis.50(4), 605–612 (2010).
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS23(13), 1679–1688 (2009).
   PubMed Web of Science ®Google Scholar
• Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS22(12), 1389–1397 (2008).
   PubMed Web of Science ®Google Scholar
• Cella D, Gilet H, Viala-Danten M, Peeters K, Dubois D, Martin S. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. HIV Clin. Trials11(1), 18–27 (2010).
   PubMed Web of Science ®Google Scholar
• Nelson M, Girard PM, Demasi R et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J. Antimicrob. Chemother.65(7), 1505–1509 (2010).
   PubMed Web of Science ®Google Scholar
• Hill A, Hemmett L, Wilson B. Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials. HIV Clin. Trials.8(5), 303–310 (2007).
   PubMed Web of Science ®Google Scholar
• Hill AM, Clotet B, Johnson M, Stoll M, Smets E. Analysis of the cost of full virological suppression for highly treatment-experienced, HIV-infected patients in the POWER trials in different European healthcare settings. Presented at: 11th European AIDS Conference (EACS). Madrid, Spain, 24–27 October 2007 (Poster P19.5/05).
   Google Scholar
• Mauskopf J, Brogan A, Smets E, Nuyts G, Martin S. Cost–effectiveness of darunavir (TMC114)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients. Presented at: 8th International Congress on Drug Therapy in HIV Infection (ICDTHI). Glasgow, UK, 12–16 November 2006 (Poster P51).
   Google Scholar
• Moeremans K, Annemans L, Smets E et al. Cost–effectiveness of DRV/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings. Presented at: 11th European AIDS Conference (EACS). Madrid, Spain, 24–27 October 2007 (Poster P4.3/08).
   Google Scholar
• Smets E, Soorapanth S, Brogan A, Mrus J. Cost-–efficacy analysis of darunavir/r vs. lopinavir/r as a first-line HIV treatment in the United States. Presented at: The 47th Annual Infectious Disease Society of America (IDSA) Meeting. Philadelphia, PA, USA, 29 October–1 November 2009.
   Google Scholar
• Red Book 2008. Red Book™ for Windows®. Version 61127, Volume 50. Thomson PDR, Montvale, NJ, USA (2008).
   Google Scholar
• Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost–efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin. Trials.11(3), 133–144 (2010).
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med.10(9), 527–535 (2009).
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W, Gazzard B. Effects of nucleoside analogues versus ritonavir boosted protease inhibitors on lipid levels – analysis of 12 clinical trials in 4231 antiretroviral naïve patients. Presented at: The XVII World AIDS Conference. Mexico City, Mexico, 3–8 August 2008 (Poster THPE0167).
   Google Scholar
• Red Book 2009. Red Book™ for Windows®. Version 61127, Volume 53. Thomson PDR, Montvale, NJ, USA (2009).
   Google Scholar